Treatment of posthepatitic cirrhosis by Fuzheng Huayu Tablet (扶正化瘀片) for reinforcing qi and resolving stasis

Xin Deng; Jian Liang; Zhen-wei Liu; Fa-sheng Wu; Xuan Li

doi:10.1007/s11655-013-1433-7

Your Location：

Home >

Browse articles >

Treatment of posthepatitic cirrhosis by Fuzheng Huayu Tablet (扶正化瘀片) for reinforcing qi and resolving stasis

OriginalPaper | Updated：2021-08-27

- Treatment of posthepatitic cirrhosis by Fuzheng Huayu Tablet (扶正化瘀片) for reinforcing qi and resolving stasis
- Treatment of posthepatitic cirrhosis by Fuzheng Huayu Tablet (扶正化瘀片) for reinforcing qi and resolving stasis
- 中国结合医学杂志（英文版） 2013年19卷第4期页码：289-296
- Affiliations：
  
  Ruikang Hospital of Guangxi University of Chinese Medical,Nanning,China
- Author bio：
- Funds：
  
  Supported by the National Natural Science Foundation of China (No. 81160433) and the Guangxi Natural Science Foundation (No. 2011GXNSFD018035 and GZKZZ1103)
- DOI：10.1007/s11655-013-1433-7
  中图分类号：
- 纸质出版日期：2013，
  
  网络出版日期：2013-4-2，
Scan for full text
Deng, X., Liang, J., Liu, Zw. et al. Treatment of posthepatitic cirrhosis by Fuzheng Huayu Tablet (扶正化瘀片) for reinforcing qi and resolving stasis., Chin. J. Integr. Med. 19, 289–296 (2013). https://doi.org/10.1007/s11655-013-1433-7

Xin Deng, Jian Liang, Zhen-wei Liu, et al. Treatment of posthepatitic cirrhosis by Fuzheng Huayu Tablet (扶正化瘀片) for reinforcing qi and resolving stasis[J]. Chinese Journal of Integrative Medicine, 2013,19(4):289-296.
Deng, X., Liang, J., Liu, Zw. et al. Treatment of posthepatitic cirrhosis by Fuzheng Huayu Tablet (扶正化瘀片) for reinforcing qi and resolving stasis., Chin. J. Integr. Med. 19, 289–296 (2013). https://doi.org/10.1007/s11655-013-1433-7 DOI：

Xin Deng, Jian Liang, Zhen-wei Liu, et al. Treatment of posthepatitic cirrhosis by Fuzheng Huayu Tablet (扶正化瘀片) for reinforcing qi and resolving stasis[J]. Chinese Journal of Integrative Medicine, 2013,19(4):289-296. DOI： 10.1007/s11655-013-1433-7.

摘要

To investigate the efficacy and safety of the Fuzheng Huayu Tablet (扶正化瘀片

FZHYT)

which is used to reinforce qi and resolve stasis in patients with posthepatitic cirrhosis (PHC). A multicenter

randomized

controlled clinical trial was conducted in 180 patients with PHC. The patients were randomly assigned using random numbers to a treatment group treated with FZHYT and a placebo group; the treatment course was 6 months for both groups. Overall response

adverse events (AEs)

and the 2-year survival rate were assessed after treatment. Evaluations were made on changes in liver function

liver fibrosis

coagulation

hemodynamics

degrees of esophagogastric varices

ascites

quality of life (QOL)

and scores of main symptoms. The overall response was significantly higher in the treatment group than the placebo group (86.7% vs. 62.2%

P<0.01). Patients in both groups had significant improvements in liver function [total bilirubin (TBIL)

albumin (ALB)]

liver fibrosis [hyaluronic acid (HA)

type IV collagen (CIV)]

coagulation [prothrombin time (PT)

activated partial thromboplastin time (APTT)

fibrinogen (FIB)

and thrombin time (TT)]

hemodynamics portal venous flow (PVF)

and splenic vein flow (SVF) after treatment. Between-group comparisons showed that compared with the placebo group patients in the treatment group achieved significantly greater improvements in TBIL

ALB

C IV

APTT

PVF

SVF

time to ascites resolution

2-year survival

QOL

and symptom scores (P<0.05 or P<0.01). There were no significant AEs during the treatment. FZHYT is effective and safe for the treatment of hepatic cirrhosis as it is associated with improved liver function

liver fibrosis

coagulation

portal hypertension state

QOL

2-year survival rate

and fewer AEs.

Abstract

To investigate the efficacy and safety of the Fuzheng Huayu Tablet (扶正化瘀片

FZHYT)

which is used to reinforce qi and resolve stasis in patients with posthepatitic cirrhosis (PHC). A multicenter

randomized

adverse events (AEs)

and the 2-year survival rate were assessed after treatment. Evaluations were made on changes in liver function

liver fibrosis

coagulation

hemodynamics

degrees of esophagogastric varices

ascites

quality of life (QOL)

and scores of main symptoms. The overall response was significantly higher in the treatment group than the placebo group (86.7% vs. 62.2%

P<0.01). Patients in both groups had significant improvements in liver function [total bilirubin (TBIL)

albumin (ALB)]

liver fibrosis [hyaluronic acid (HA)

type IV collagen (CIV)]

coagulation [prothrombin time (PT)

activated partial thromboplastin time (APTT)

fibrinogen (FIB)

and thrombin time (TT)]

hemodynamics portal venous flow (PVF)

and splenic vein flow (SVF) after treatment. Between-group comparisons showed that compared with the placebo group patients in the treatment group achieved significantly greater improvements in TBIL

ALB

C IV

APTT

PVF

SVF

time to ascites resolution

2-year survival

QOL

liver fibrosis

coagulation

portal hypertension state

QOL

2-year survival rate

and fewer AEs.

关键词

posthepatitic cirrhosisFuzheng Huayu Tabletblood-activatingstasis-resolvingclinical trial

Keywords

posthepatitic cirrhosisFuzheng Huayu Tabletblood-activatingstasis-resolvingclinical trial

references

Seung HP, Dong JK, Jae YC, Cho SW, Hwang SG, Lee YJ, et al. Non-invasive markers to diagnose cirrhosis in patients with HBeAg positive chronic hepatitis: Do new biomarkers improve the accuracy? Clin Biochem 2010;43:877–881.

Sophie L, Boris J, Fatima T-C, Pascale G, Ariane M. Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol 2005;45:605–628.

Li WY, Jiang YF, Jin QL, Zhang H, Feng XW, Niu JQ. Immunologic characterization of posthepatitis cirrhosis caused by HBV and HCV infection. J Biomed Biotechnol doi:10.1155/2010/138237.

Anna S, Brian J. Chronic hepatitis B. Hepatology 2007;45:507–538.

Ganne-Carrié N, Ziol M, de Ledinghen V, Douvin C, Marcellin P, Castera L, et al. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 2006;44:1511–1517.

Jordi B, Morris S, Josep M. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001;35:421–430.

Lu ZY, Zhong NS, eds. Internal medicine. 7th ed. Beijing: People’s Medical Publishing House; 2008:446–454.

Yang HZ, Wang FL, Wang YZ, Shen WS, Xu GL, Yang YW, et al. The clinical study on chronic hepatitis B treated by the four-step therapeutics of traditional Chinese medicine. Chin Med Mater (Chin) 2006;29:748–752.

Shi WQ, Ru QJ, Cai GY. Effect of umbilical sticking therapy with Qitou Xiaogu plaster in treating liver cirrhosis patients with portal hypertension. Chin J Integr Tradit West Med (Chin) 2008;28:642–645.

Deng X, Liang J, Wu FS, Li YB, Tang FY. Effects of traditional Chinese medications on quality of life in patients with liver cirrhosis. Lishizhen Med Mater Med Res (Chin) 2010;21:3314–3316.

Luk JM, Wang X, Liu P, Wong KF, Chan KL, Tong Y, et al. Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: from laboratory discovery to clinical evaluation. Liver Int 2007;27:879–890.

Li YM, Yang HZ, Guan WB, Ke QS, Dai M, Xie HP, et al. Therapeutic effect of traditional Chinese medicine on coagulation disorder and accompanying intractable jaundice in hepatitis B virus-related liver cirrhosis patients. World J Gastroenterol 2008;14:6060–6064.

Huang J, Huang H, Jiao Y, Ai G, Huang T, Li L, et al. Effect of Anluohuaxian Tablet combined with gamma-IFN on schistosomal liver fibrosis. J Huazhong Univ Sci Technol Med Sci (Chin) 2009;29:53–58.

Tong GD, Zhou DQ, He JS, Zhang L, Chen ZF, Xiao CL, et al. Clinical research on navel application of Shehuang Paste combined with Chinese herbal colon dialysis in treatment of refractory cirrhotic ascites complicated with azotemia. World J Gastroenterol 2006;12:7798–7804.

Wen J, Shen WL, Yang SH. Adjuvant hepatic chemotherapy after resection of solitary hepatocellular carcinoma associated with hepatitis B virus cirrhosis. Hepatobiliary Pancreat Dis Int 2006;5:224–227.

Digestive Disease Committee, Chinese Association of Integrative Medicine. Program for diagnosis and treatment of liver cirrhosis with integrative Chinese and Western medicine (draft). Chin J Integr Tradit West Med (Chin) 2004;24:869–871.

Society of Infectious and Parasitic diseases and Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of viral hepatitis. Chin J Infect Dis (Chin) 2001;19(1):56–62.

WHO. World Health Organisation WHOQOL-BREF: introduction, administration, scoring and generic version of the assessment. Geneva, 1996.

Hao YT, Fang JQ. Chinese version of WHOQOL: introduction and administration. Modern Rehabil (Chin) 2000;4:1123–1124.

Digestive Disease Committee, Chinese Association of Integrative Medicine. Criteria for clinical diagnosis, syndrome differentiation and response evaluation for liver cirrhosis (trial edition). Chin J Integr Tradit West Med (Chin) 1994;14:237–238.

State Administration of Traditional Chinese Medicine of the People’s Republic of China. Criteria for diagnosis and treatment of diseases in traditional Chinese medicine. Nanjing: Nanjing University Press; 1994:276.

Cai L, Wen LM, Qin G, Chen P, Chen JP. Endoscopic injection of domestically produced tissue adhesives combined with ligation in the treatment of esophagogastric varices. J Milit Surg Southwest China (Chin) 2010;12:866–867.

Ren JX. An investigation into incubative pathogen. Chin Med Mod Dist Educ China (Chin) 2003;6(2):8–9.

Kuang WH. An introduction to the experience of Professor XU Xin-mei in treating chronic hepatitis B. J New Chin Med (Chin) 2006;38(9):13–14.

Gu J, Hong JH, Xu LM, Zhang Q. Effects of “Fuzheng Huayu Capsule” on portal hemodynamics in patients with liver cirrhosis. Shanghai J Tradit Chin Med (Chin) 2005;39(11):31–32.

Wang Y. Effects of “Fuzheng Huayu Capsule” on liver fibrosis in 60 patients. Shaanxi J Tradit Chin Med (Chin) 2011;32:1117–1118.

Zhu XL. Clinical observation of effects of “Fuzheng Huayu Capsule” on liver fibrosis. China Pract Med (Chin) 2011;6:136–137.

Xia XF. Clinical observation of effects of “Fuzheng Huayu Capsule” on portal hypertension in patients with liver cirrhosis. J Emerg Tradit Chin Med (Chin) 2010;19:1119–1120.

Moller S, Hobolth L, Winkler C, Bendtsen F, Christensen E. Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis. Gut 2011;1254–1259.

Park S, Kim SH, Ropella GE, Roberts MS, Hunt CA. Trancing multiscale mechanisms of drug disposition in normal and diseased livers. J Pharmacol Exp Ther 2010;334:124–136.

Rossle M, Gerbes A. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut 2010;59:988–1000.

Kim YK, Kim YK, Shim SS. Thoracic complications of liver cirrhosis: radiologic findings. Radio Graph 2009;29:825–837.

Li WW, Li Q, Wang JB, Li XY, Zhang LX, An Y, et al. A study of the quality of life in patients with hepatitis B. Chin J Hepatol (Chin) 2007;15:312–313.

Liang R, Liu XY, Zhang HQ, Li TH. Quality of life in patients with liver cirrhosis survey. Mod Prevent Med (Chin) 2011;38:1884–1885.

FULL TEXT LINK

More>

浏览量

1005

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Effect of chinese traditional healthcare exercises on 136 junior school students

Review of the regulations for clinical research in herbal medicines in USA

Effect of two Chinese medicinal compounds, blood-activating and water-draining medicine, on tumor necrosis factor α and nuclear factor κ B expressions in rats with intracerebral hemorrhage

The investigation of the correlation between metabolic syndrome and Chinese medicine constitution types in senior retired military personnel of the People’s Liberation Army

Influence of Fuzheng Huayu Tablet (扶正化瘀片) on mental state and social function of patients with post-hepatitis B liver cirrhosis